OncoMatch

OncoMatch/Clinical Trials/NCT07379476

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Is NCT07379476 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Osimertinib alone for lung cancer (nsclc).

Phase 2RecruitingChinese University of Hong KongNCT07379476Data as of May 2026

Treatment: Osimertinib aloneThis is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: EGFR exon 19 deletion

Required: EGFR l858r

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first line for stage IV disease

Receive first line osimertinib monotherapy for stage IV disease

Lab requirements

Blood counts

haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 10^9/L, platelet count ≥100 x 10^9/L

Kidney function

creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation

Liver function

bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN

Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 10^9/L, platelet count ≥100 x 10^9/L; Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN; Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify